Pipeline

ADCETRIS^® Development Collaboration

We are developing brentuximab vedotin in collaboration with Millennium: The Takeda Oncology Company.

Learn more

Collaboration Opportunities

If you are interested in learning
more about collaboration opportunities with Seattle Genetics, please contact our Business Development team. We are also actively evaluating potential in-licensing opportunities for cancer therapeutics.

Email Business Development,
or call 425-527-4000.

Expanding our opportunities through collaboration

Seattle Genetics has entered into multiple collaborations for its antibody-drug conjugate (ADC) technology with industry-leading biotechnology and pharmaceutical companies. There are currently more than 10 collaborator ADC programs in clinical development utilizing Seattle Genetics' technology. Our ADC technology licensing agreements have generated more than $200 million to date.

In addition to the financial benefit, these licensing activities extend the reach of our technology into additional programs through collaborator development. Additionally, in some cases, they provide us with future pipeline opportunities through co-development or opt-in rights to new ADC product candidates. We have two types of ongoing ADC collaborations:

ADC License Agreements

Under our ADC license agreements with AbbVie (formerly Abbott), Agensys, Bayer, Celldex, Daiichi-Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, Seattle Genetics is entitled to receive upfront payments, milestones and royalties on net sales of any resulting ADC products. We have the potential to receive more than $3 billion in future milestone payments across our ADC collaborations. Our licensees are responsible for all development, manufacturing and commercialization activities under these collaborations.

ADC Co-Development Agreements

Our ADC co-development agreements with Agensys and Genmab provide Seattle Genetics with opportunities to supplement our internal pipeline through opt-in rights to 50:50 co-development and profit-sharing for ADC product candidates. Under our Agensys deal, we are co-developing ASG-5ME and ASG-22ME and have an opt-in right to one additional ADC program upon IND submission. Through our Genmab deal, we have opt-in rights to one ADC program at completion of phase 1 clinical trials. Under both deals, if we do not opt-in, we are entitled to receive milestones and royalties on net sales of any resulting ADC products.

We have also formed a strategic collaboration with Oxford BioTherapeutics (OBT) to jointly discover novel ADCs for cancer. Under the collaboration, OBT will generate panels of monoclonal antibodies against novel tumor-specific antigens identified using its proprietary Oxford Genome Anatomy Project database. The antibodies generated by OBT will then be screened for activity using our ADC technology. The resulting ADCs may be selected by each company for further development and commercialization.

ADC COLLABORATOR PIPELINE

	Program	Preclinical	Phase 1	Phase 2	Pivotal/ Phase 3
	Anti-CD22 (RG7593, DCDT2980S)	Non-Hodgkin lymphoma
	Anti-CD79b (RG7596, DCDS4501A)	Non-Hodgkin lymphoma
	Anti-STEAP1 (RG7450, DSTP3086S)	Prostate cancer
	Anti-MUC16 (RG7458, DMUC5754A)	Ovarian cancer
	Anti-NaPi2b (RG7599, DNIB0600A)	NSCLC, ovarian cancer
	RG7598	Multiple myeloma
	RG7600	Pancreatic, ovarian cancer
	RG7636	Melanoma
	Multiple ADCs	Cancer
	Anti-GPNMB ADC	Breast cancer, melanoma
	Anti-PSMA ADC	Prostate cancer
	Anti-CA9 ADC	Solid tumors
	Anti-AGS-16 ADC	Renal cell carcinoma
	ASG-5ME	Pancreatic, prostate, gastric cancer
	ASG-22ME	Solid tumors
	Multiple ADCs	CancerOne opt-in at IND submission
	Anti-GCC ADC	Gastrointestinal malignancies
	Undisclosed ADC	Squamous cell tumors
	Undisclosed ADCs	Cancer
	Undisclosed ADC	Solid tumors
	Multiple ADCs	Cancer
	Anti-TF ADC	Solid tumorsOpt-in at end of phase 1
	Undisclosed ADC	Cancer
	ADCs	CancerPicking pool opt-ins